Spark Therapeutics, Inc. (ONCE) Earns Outperform Rating from Analysts at Royal Bank Of Canada

Royal Bank Of Canada initiated coverage on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a research report report published on Thursday, MarketBeat.com reports. The firm issued an outperform rating and a $100.00 target price on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Jefferies Group LLC reissued a buy rating and issued a $95.00 price target (up previously from $85.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Evercore ISI assumed coverage on shares of Spark Therapeutics in a research note on Wednesday, August 16th. They issued an in-line rating and a $83.00 price target on the stock. Zacks Investment Research raised shares of Spark Therapeutics from a strong sell rating to a hold rating in a research note on Wednesday, July 19th. Chardan Capital reissued a neutral rating on shares of Spark Therapeutics in a research note on Monday, July 24th. Finally, BidaskClub raised shares of Spark Therapeutics from a sell rating to a hold rating in a research note on Thursday, June 22nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and fifteen have issued a buy rating to the company’s stock. Spark Therapeutics currently has an average rating of Buy and an average price target of $84.78.

Spark Therapeutics (NASDAQ:ONCE) opened at 81.88 on Thursday. Spark Therapeutics has a 12 month low of $35.07 and a 12 month high of $86.86. The company’s market cap is $2.56 billion. The company’s 50 day moving average is $82.07 and its 200-day moving average is $73.77.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. During the same period in the prior year, the business posted ($1.04) EPS. Spark Therapeutics’s revenue was up 14.7% compared to the same quarter last year. On average, analysts expect that Spark Therapeutics will post ($7.69) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://sportsperspectives.com/2017/09/18/spark-therapeutics-inc-once-earns-outperform-rating-from-analysts-at-royal-bank-of-canada.html.

In other news, CEO Jeffrey D. Marrazzo sold 9,331 shares of the business’s stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $65.00, for a total transaction of $606,515.00. Following the transaction, the chief executive officer now owns 230,534 shares of the company’s stock, valued at approximately $14,984,710. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Stephen W. Webster sold 2,337 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $71.12, for a total transaction of $166,207.44. Following the transaction, the chief financial officer now directly owns 4,837 shares in the company, valued at approximately $344,007.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 362,497 shares of company stock worth $26,158,631. Corporate insiders own 7.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. boosted its position in shares of Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Spark Therapeutics during the 2nd quarter valued at about $143,000. BNP Paribas Arbitrage SA boosted its position in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 2,449 shares during the last quarter. Pacad Investment Ltd. boosted its position in shares of Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Highbridge Capital Management LLC acquired a new position in shares of Spark Therapeutics during the 1st quarter valued at about $227,000. 91.01% of the stock is currently owned by hedge funds and other institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply